We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer.
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We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer.
Patients and Methods
This was a single-center, phase III, randomized controlled trial (ClinicalTrials.gov identifier: NCT00193739). Eligible patients were between 18 and 65 years old and had stage IB2, IIA, or IIB squamous cervical cancer. They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks. Patients in the neoadjuvant group received postoperative adjuvant radiation or concomitant chemotherapy and radiotherapy, if indicated. The primary end point was disease-free survival (DFS), defined as survival without relapse or death related to cancer, and secondary end points included overall survival and toxicity.
Results
Between September 2003 and February 2015, 635 patients were randomly assigned, of whom 633 (316 patients in the neoadjuvant chemotherapy plus surgery group and 317 patients in the concomitant chemoradiation group) were included in the final analysis, with a median follow-up time of 58.5 months. The 5-year DFS in the neoadjuvant chemotherapy plus surgery group was 69.3% compared with 76.7% in the concomitant chemoradiation group (hazard ratio, 1.38; 95% CI, 1.02 to 1.87; P = .038), whereas the corresponding 5-year OS rates were 75.4% and 74.7%, respectively (hazard ratio, 1.025; 95% CI, 0.752 to 1.398; P = .87). The delayed toxicities at 24 months or later after treatment completion in the neoadjuvant chemotherapy plus surgery group versus the concomitant chemoradiation group were rectal (2.2% v 3.5%, respectively), bladder (1.6% v 3.5%, respectively), and vaginal (12.0% v 25.6%, respectively).
Conclusion
Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer.
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INTRODUCTION
Cervical cancer is a major public health problem worldwide, 1 and squamous carcinoma is the most common subtype. Patients with International Federation of Gynecology and Obstetrics (FIGO) stages IB2 to IVA disease are considered to have locally advanced cancer. Radiotherapy is the primary modality of treatment, although definitive surgery can also be performed in patients with stage IB2 or IIA disease. 2 The treatment of cervical cancer underwent a paradigm shift when several trials proved that administration of concomitant chemotherapy with definitive radiotherapy improved survival compared with only radiation. [3] [4] [5] [6] [7] Although one trial 8 failed to demonstrate its benefit, based on cumulative evidence, 9,10 concomitant platinum-based chemotherapy and radiotherapy has been the standard treatment of locally advanced cervical cancer since 1999. However, 25% to 40% of patients still experience relapse, and some experience distant failure despite local control after chemoradiation 10 ; in addition, this treatment is associated with early and long-term toxicity. Thus, there is a need for further improvement in outcomes, but few definitive studies of new therapeutic strategies have been reported in the past two decades.
The use of neoadjuvant chemotherapy followed by radical hysterectomy has been considered an attractive approach to improve disease control and reduce toxicity. Cervical cancer has a high response rate to modern chemotherapy including taxane and platinum agents.
11 Neoadjuvant chemotherapy has the potential to eradicate micrometastases and could reduce systemic failures, in addition to facilitating local control by surgical resection. Some studies and a meta-analysis suggested that neoadjuvant chemotherapy followed by surgery could improve survival outcomes compared with radiotherapy.
12-14 However, radiotherapy without concomitant chemotherapy became an obsolete standard, and the chemotherapy regimens used in these studies were not contemporary. Neoadjuvant chemotherapy before definitive radiotherapy failed to show benefit, 15,16 possibly because of selection of radiotherapy-resistant clones, but there is potentially no such interaction between chemotherapy and surgery. Although promising, the neoadjuvant chemotherapy plus surgery approach lacks adequate evidence but continues to be practiced in many parts of the world.
17,18
Therefore, we conducted a randomized controlled trial to compare neoadjuvant chemotherapy, using a contemporary regimen of paclitaxel and carboplatin, followed by radical surgery versus concomitant chemoradiation in patients with stage IB2, IIA, or IIB squamous cervical cancer.
PATIENTS AND METHODS
Study Design and Patients
This study was designed as a prospective, single-center, two-group, open-label, phase III, randomized controlled trial. Women between 18 and 65 years of age with newly diagnosed, previously untreated, histopathologically proven squamous cell carcinoma of the uterine cervix with 1994 FIGO stage IB2, IIA, or IIB disease were included in the study. In addition, the Eastern Cooperative Oncology Group performance status was # 1, there was no evidence of distant metastases, and hematologic and biochemical parameters, including renal function, were adequate.
The study was designed by faculty member investigators belonging to the Gynecologic Oncology Disease Management Group of Tata Memorial Centre (Mumbai, India) and approved by the institutional human ethics committee. Written informed consent was obtained from all patients before inclusion in the study. The study protocol and amendments are available in the Data Supplement.
Random Assignment
Eligible patients were randomly assigned to either study group in a 1:1 ratio with the use of a computerized block design with a block size of 4. Random assignment was performed by the Clinical Trials Unit of Tata Memorial Centre. Patients were stratified according to clinically determined 1994 FIGO stage IB2, IIA, or IIB disease before random assignment. Study investigators and patients were not blinded to treatment allocation.
Study Procedures
All patients underwent punch biopsy to establish diagnosis and a detailed clinical examination, including a pelvic examination by two clinicians, to determine initial stage. Patients underwent examination under anesthesia, if required. Patients also underwent blood tests and either computed tomography scan or ultrasonography of the abdomen and pelvis before random assignment.
Patients randomly assigned to the neoadjuvant chemotherapy plus surgery group received three cycles of paclitaxel (175 mg/m 2 ) and carboplatin (dosed to an area under curve of 5 to 6) once every 3 weeks. Patients underwent clinical response assessment after the second and third cycles of chemotherapy. Patients who had no response or disease progression at these time points were crossed over to receive definitive concomitant chemotherapy and radiotherapy, whereas responders underwent surgery 3 to 4 weeks after the third cycle of chemotherapy.
Patients assigned to the neoadjuvant chemotherapy plus surgery group underwent Piver-Rutledge class III radical abdominal hysterectomy, bilateral pelvic lymphadenectomy, and lower para-aortic lymph node sampling by expert gynecologic oncologists. Surgery was abandoned in patients with intraoperative findings of either unresectable primary tumor or lymph node disease, and these patients were treated with definitive concomitant chemoradiation.
Patients assigned to the concomitant chemoradiation group and those who were crossed over from the neoadjuvant chemotherapy plus surgery group received standard external-beam radiation to the whole pelvis and brachytherapy. They received an external radiation dose of 40 Gy in 20 fractions with 2 Gy per fraction and a midline shield at 20 Gy, followed by intracavitary radiation to point A as follows: either two applications of a low dose rate of 30 Gy each or five applications of a high dose rate of 7 Gy each. Radiation doses were modified to respect tumor, rectal, and bladder constraints. These patients also received five cycles of cisplatin (40 mg/m 2 ), administered once every week starting with external-beam radiotherapy.
Patients in the neoadjuvant chemotherapy plus surgery group who underwent radical hysterectomy were given adjuvant therapy (radiotherapy or concomitant chemotherapy and radiotherapy) as per protocoldefined criteria, in accordance with published evidence. 7, 19 On the basis of histopathologic evaluation of the surgical specimen, adjuvant chemoradiation was given in the presence of any one of the following features: lymph node metastasis, positive surgical margins, or parametrial involvement. Adjuvant radiotherapy alone was given based on the presence of any two of the following features: deep cervical stromal invasion, lymphovascular invasion, or tumor size . 4 cm. Patients in both groups were evaluated at protocol-defined time points to evaluate response, monitor for relapse, and assess toxicity.
Outcomes
The primary end point of the study was disease-free survival (DFS), which was defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site (local, distant, or both) or second primary cancer or death related to cancer (including toxicity), whichever occurred first. Patients who died of causes unrelated to cancer or of unknown cause were censored at the time of their death in the analysis of primary end point. An additional analysis that included death as a result of any cause (if it was the first event) in the definition of a DFS event was also performed. The secondary end points of the study were overall survival (OS), which was defined as the time interval between the date of random assignment and the date of death from any cause, and toxicity, which was defined according to Common Terminology Criteria for Adverse Events (version 2.0). First recurrences were categorized as local if they were confined to the pelvic region including the vagina, jco.org pelvic lymph nodes, and/or other pelvic tissues; as distant if they were located outside the pelvis; or as local plus distant if they occurred in both regions simultaneously.
Statistical Analysis
The study was planned based on an expected 5-year DFS rate of 65% in the concomitant chemoradiation group with an absolute increase of 10 percentage points in the neoadjuvant chemotherapy plus surgery group at an a level of .05 and statistical power of 80%, using a two-sided test. The final sample size was 730 patients, which accounted for a 10% rate of patients lost to follow-up. Because of the long recruitment period and slower than anticipated recruitment, the study team, with the approval of the institutional ethics committee, decided to close study accrual as of February 2015 and analyze the study for its primary end point after followup of at least 2 years for the last randomly assigned patient. The final accrued patient population constitutes 87% of the planned sample size. The current report is the first analysis of this study.
The primary and secondary end points related to survival were assessed in the intent-to-treat population, estimated using the KaplanMeier method, and tested by means of a two-sided log-rank test. Analysis of DFS was performed in subgroups that were defined according to the stratification factor of 1994 FIGO stage (IB2, IIA, or IIB), as well as other prognostic factors (hemoglobin level . or # 11 g/dL, Eastern Cooperative Oncology Group performance status of 0 or 1, and radiologic pelvic lymph node status [negative or positive]), using univariable Cox analysis. A Cox proportional hazards model was used to perform multivariable analysis of various factors affecting DFS and OS, including study intervention. All analyses were performed using SPSS Statistics for Windows software, version 20.0 (SPSS, Chicago, IL).
RESULTS
Patients
From September 2003 through February 2015, we evaluated 1,713 patients for potential participation in the study, of whom 635 were randomly assigned (Fig 1) . After excluding two patients with eligibility violations, the present analysis reports the findings in the remaining 633 patients (316 in the neoadjuvant chemotherapy plus surgery group and 317 in the concomitant chemoradiation group). At the data cutoff point of March 2017, the median follow-up time in surviving patients was 58.5 months (interquartile range, 39.3 to 79.7 months). The number of patients lost to follow-up were 16 (5.1%) in the neoadjuvant chemotherapy plus surgery group and 13 (4.1%) in concomitant chemoradiation group. The two study groups were well balanced with respect to baseline characteristics ( Table 1) . The majority of patients had 1994 FIGO stage IIB disease (57.2%).
Treatment
There was good compliance to planned treatment in both arms, including doses and duration of chemotherapy and radiotherapy (Table 2 ). In the neoadjuvant chemotherapy plus surgery group, two patients (0.63%) received concomitant chemotherapy and radiotherapy, and in the concomitant chemotherapy and radiotherapy group, two patients (0.63%) underwent surgical resection (protocol nonadherence). In the neoadjuvant chemotherapy plus surgery group, 68 patients (21.5%) crossed over (presurgery crossover and intraoperative unresectable disease) to receive definitive concomitant chemoradiation, 42 patients (13.3%) received postoperative adjuvant chemoradiation, and 31 patients (9.8%) received postoperative adjuvant radiotherapy, according to protocol-defined criteria.
Efficacy Ninety-five DFS events (30.06%) occurred in the neoadjuvant chemotherapy plus surgery group, and 74 events (23.34%) occurred in the concomitant chemoradiation group; the corresponding 5-year DFS rates were 69.3% and 76.7%, respectively (unadjusted hazard ratio [HR] for DFS in the neoadjuvant chemotherapy plus surgery group, 1.38; 95% CI, 1.02 to 1.87; P = .038; Fig 2) . DFS was also significantly inferior in the neoadjuvant chemotherapy plus surgery group after adjusting for stage, pelvic lymph node status, age, hemoglobin level, and performance status (adjusted HR, 1.46; 95% CI, 1.08 to 1.99; P = .015; Appendix Table  A1 , online only). When the definition of a DFS event included death as a result of any cause and all randomly assigned patients (N = 635) were analyzed (sensitivity analysis), DFS showed a trend of being inferior in the neoadjuvant chemotherapy plus surgery group compared with the concomitant chemoradiation group (5-year DFS, 67.6% v 72.0%, respectively), although this comparison did not reach statistical significance (unadjusted HR in the neoadjuvant chemotherapy plus surgery group, 1.28; 95% CI, 0.97 to 1.70; P = .086; Appendix Fig A1, online only) .
In subgroup analyses, the DFS detriment in the neoadjuvant chemotherapy plus surgery group was statistically significant in patients with FIGO stage IIB disease, with a significant test of interaction between treatment effect and stages IIA and IIB disease (Fig 3 and Appendix Fig A2, online only) . In patients with stage IIB disease, the 5-year DFS rates in the neoadjuvant chemotherapy plus surgery and concomitant chemoradiation groups were 67.2% and 79.3%, respectively (unadjusted HR for DFS in the neoadjuvant chemotherapy plus surgery group, 1.90; 95% CI, 1.25 to 2.89; P = .003).
Eighty patients (25.32%) died in the neoadjuvant chemotherapy plus surgery group, and 80 patients (25.24%) died in the concomitant chemotherapy plus radiotherapy group, with corresponding 5-year OS rates of 75.4% and 74.7%, respectively (unadjusted HR for death in the neoadjuvant chemotherapy plus surgery group, 1.025; 95% CI, 0.752 to 1.398; P = .87; Fig 2; Appendix Table A2 , online only). There was no difference in OS between the two groups after adjusting for stage, pelvic lymph node status, age, hemoglobin level, and performance status (adjusted HR, 1.06; 95% CI, 0.77 to 1.44; Appendix Table A3 , online only).
The pattern of first recurrence in the two study groups is provided in Appendix Table A4 (online only). Overall, 18.67% of patients (59 in 316 patients) in the neoadjuvant chemotherapy plus †Low dose rate-equivalent doses calculated using high dose rate to low dose rate conversion factor of 1/0.54.
jco.org surgery group and 13.56% of patients (43 of 317 patients) in the concomitant chemoradiation group experienced local (with or without distant) first recurrences. Treatment at relapse, by study group, in patients with DFS events is listed in Appendix Table A5 (online only).
Toxicity
The early adverse events during or within 42 days of treatment completion are listed in Table 3 . Treatment in both study groups was generally well tolerated. In the neoadjuvant chemotherapy plus surgery group, grade 3 or 4 thrombocytopenia occurred at a higher rate than in the concomitant chemoradiation group (3.5% v 0.3%, respectively; P = .003), but there was no significant difference between the two study groups with respect to grade 3 or 4 GI and bladder toxicities. In the neoadjuvant chemotherapy plus surgery group, perioperative hemorrhage with . 1,000 mL of blood loss occurred in 7.9% of patients.
The cumulative late adverse events of any grade are listed in Table 4 . In the neoadjuvant chemotherapy plus surgery group, compared with the concomitant chemoradiation group, there was a lower rate of rectal (5.7% v 13.3%, respectively; P = .002), bladder A .79 Fig 3 . Disease-free survival (DFS) of subgroups. P values are for the interaction term from a model with study arm, the subgroup variable, and arm 3 subgroup interaction term. DFS hazard ratios are indicated by diamonds, and 95% CIs are indicated by the crossing horizontal lines. Diamond size is proportional to each patient subgroup population size. All hazard ratios (HR) are unadjusted. CTRT, concomitant chemoradiation; NACT, neoadjuvant chemotherapy.
P for Interaction
(2.8% v 7.3%, respectively; P = .017), and vaginal (19.9% v 36.9%, respectively; P , .001) toxicity occurring or persisting 90 days after treatment completion. However, 24 months after treatment completion, there was no difference in rectal and bladder toxicities between the two groups, whereas vaginal toxicity continued to occur at a lower rate in the neoadjuvant chemotherapy plus surgery group (12.0% v 25.6% in the concomitant chemoradiation group; P , .001).
DISCUSSION
We report here the outcomes of, to our knowledge, the first randomized study that has compared neoadjuvant chemotherapy followed by radical surgery with the current standard treatment of concomitant chemoradiation in patients with locally advanced squamous cervical cancer. Treatment was delivered by expert gynecologic, medical, and radiation oncologists at a single tertiary cancer center in India. Concomitant chemoradiation resulted in an increased 5-year DFS rate compared with neoadjuvant chemotherapy and surgery, with an absolute difference of 7.4 percentage points between the groups. Subgroup analysis suggests that the main benefit of concomitant chemoradiation was in patients with stage IIB disease. There was no difference in OS between the two groups, although the study was not powered to make a definitive conclusion with respect to this end point.
This study was based on the presumption that neoadjuvant taxane plus platinum chemotherapy will substantially reduce the risk of distant recurrence and facilitate local control with surgery compared with chemoradiation. However, our results do not fulfill the promise that the neoadjuvant chemotherapy plus surgical strategy showed when it was compared with radiotherapy alone.
12-14 It is worth noting that the control group in our study included concomitant cisplatin chemotherapy at a cumulative dose of up to 200 mg/m 2 , which is likely to have provided a level of systemic control that could not be further improved by the neoadjuvant chemotherapy regimen. The results suggest that it is unlikely that addition of more chemotherapy, over and above that used in concomitant chemoradiation, will further improve survival in patients with locally advanced cervical cancer. In this context, results of three ongoing studies evaluating the role of chemotherapy will be of interest (ClinicalTrials.gov identifiers: NCT00039338, NCT01414608, and NCT01566240). A European Organisation for Research and Treatment of Cancer study (ClinicalTrials.gov identifier: NCT00039338) is testing the same NOTE. Adverse events were assessed using the National Cancer Institute Common Toxicity Criteria Version 2.0. Some patients had more than one adverse event.
Abbreviations: CTRT, concomitant chemotherapy and radiotherapy; NA, not applicable; NACT, neoadjuvant chemotherapy. NOTE. Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 2.0. Some patients had more than one adverse event.
Abbreviations: CTRT, concomitant chemotherapy and radiotherapy; NACT, neoadjuvant chemotherapy. *Vaginal adverse events included synechiae, stenosis, and fibrosis. †Other adverse events included lymphedema, hernia, and intestinal obstruction.
jco.org question of neoadjuvant chemotherapy followed by surgery versus concomitant chemoradiation in patients with stage IB and II disease using cisplatin-based neoadjuvant chemotherapy regimens. A second study (ClinicalTrials.gov identifier: NCT01414608) is testing four cycles of paclitaxel plus carboplatin as adjuvant treatment after concomitant chemoradiation. Another previously reported randomized study has reported improvements in DFS and OS with the use of concomitant and adjuvant gemcitabine and cisplatin chemotherapy, 20 but this has not become standard practice because of excessive toxicity. In our study, the majority of first recurrences (102 of 162 recurrences, 62.96%) were local (with or without distant; Appendix Table A4 ), attesting to the importance of good local control. There has been continuing interest in the use of surgery in patients with locally advanced cervical cancer.
14,17,18,21,22 Despite adequate neoadjuvant chemotherapy, surgery was possible in only 227 patients (72.15%) in the neoadjuvant chemotherapy plus surgery group, similar to the ongoing European Organisation for Research and Treatment of Cancer randomized study, 23 which has reported a 76% surgical resection rate. Our study results indicate that the surgical strategy does not improve the local control rate compared with concomitant chemoradiation. Moreover, many surgical patients (32.2%) required adjuvant radiation or chemoradiation, resulting in trimodality treatment in a considerable fraction of patients in this group.
A number of reasons could explain the outcomes of our study. A post hoc analysis of our data suggests that DFS in patients who were unable to undergo surgery and crossed over to concomitant chemoradiation is inferior compared with patients who could undergo surgery (HR, 1.49; 95% CI, 0.94 to 2.38; P = .089; Appendix Fig A3, online only) . Another post hoc analysis in the neoadjuvant chemotherapy plus surgery group patients who were able to undergo surgery (227 of 316 patients) suggests that patients who received adjuvant radiation or concomitant chemoradiation had inferior DFS compared with patients who did not (HR, 1.69; 95% CI, 1.02 to 2.80; P = .04; Appendix Fig A4, online only) . Although prognostically poor by selection, it is possible that delaying definitive chemoradiation and/or induction of crossresistance between chemotherapy and radiation were detrimental for disease control in these patient subgroups. It could be argued that cisplatin may have been more efficacious than carboplatin when combined with paclitaxel. In a Japanese study in the recurrent or metastatic setting, 24 paclitaxel plus carboplatin was noninferior to paclitaxel plus cisplatin in the full population, but the latter regimen resulted in higher OS in the platinum-naïve subgroup. However, a subgroup analysis cannot be considered definitive. Moreover, the two regimens were different not only with respect to platinum but also paclitaxel dose and administration schedule. Thus, the choice of platinum drug is unlikely to be a critical factor in the outcome of our study. An ongoing randomized study (ClinicalTrials.gov identifier: NCT01414608) is also using paclitaxel plus carboplatin as the adjuvant regimen.
Treatment in both groups was well tolerated, and adverse events were within acceptable limits. Of note, the rates of severe grades of nonhematologic early toxicities were not significantly different between the two study groups. Although late toxicities beyond 3 months involving the bladder and rectum were higher in the concomitant chemoradiation group, there was no significant difference at 24 months or later, indicating their resolution in most patients. Only vaginal toxicity continued to be significantly higher in the concomitant chemoradiation group at 24 months or later.
This study has some limitations. We included patients with different disease stages, and the analysis is not powered to definitely answer the question in patients with operable cervical cancer (stages IB2 and IIA). Quality of life was not prospectively measured and could have elucidated the relative effect of two treatment strategies on this outcome.
Our study has answered a long-standing and important clinical question in the treatment of patients with locally advanced cervical cancer. Concomitant chemoradiation using single-agent weekly cisplatin results in a significantly increased DFS rate compared with neoadjuvant chemotherapy followed by radical surgery in this patient population.
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